The views expressed in this correspondence are those of the authors and do not necessarily represent official policy of the US Food and Drug Administration.

No potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patrick R. Harrington, Russell Fleischer, Sarah M. Connelly, Linda L. Lewis, and Jeffrey Murray
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

References


2. Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Ribavirin reduces absolute lymphocyte...


Correspondence: P. R. Harrington, FDA/CDER/OAP/DAVP, 10903 New Hampshire Ave, Bldg 22 Rm 6336, Silver Spring, MD 20993 (patrick.harrington@fda.hhs.gov).

Clinical Infectious Diseases 2016;62(4):528–9
Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US. DOI: 10.1093/cid/civ905